Neoepitope Expression in Epithelial Cancer: ntification of Apoptosis in Circulating R or Cells by CellSearch Analysis

wnloaded pose: This study aimed to detect the M30 neoepitope on circulating tumor cells (CTC) as a tool for ifying apoptotic CTC throughout disease course and treatment. erimental Design: An automated sample preparation and analysis platform for computing CTC earch) was integrated with a monoclonal antibody (M30) targeting a neoepitope disclosed by e cleavage at cytokeratin 18 (CK18) in early apoptosis. The assay was validated using cell lines lood samples from healthy volunteers and patients with epithelial cancer. ults: M30-positive CTC could be detected in >70% of CTC-positive carcinoma patients, which were r both chemotherapy and radiologic treatments. The fraction of M30-positive CTC varied from 50% , depending on the histotype. To investigate the potential application of the M30 CTC assay for the tion of response in early phase trials, CTC and M30-positive CTC were enumerated in a small case of breast cancer patients during treatment. Results indicate that changes in the balance of M30ve/positive CTC may be used as a dynamic parameter indicating an active disease, as documented sistent radiologic findings. clusions: M30 expression on CTC is detectable by immunofluorescence. The M30-integrated as potential for monitoring dynamic changes in the quote of apoptotic CTC (in addition to CTC ) to evaluate response in clinical trials of molecularly targeted anticancer therapeutics as well as count for translational research, in which there is a pressing need for informative circulating biomarkers. Clin Cancer Res; 16(21); 5233–43. ©2010 AACR.